Royalty Pharma officer plans $3.47M share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Royalty Pharma plc (RPRX) common shares are subject to a planned sale of 64,399 shares by TPC RP EPA1 LLC for the account of Terrance Coyne, an officer. The approximate sale date is May 26, 2026, and the reported aggregate market value is $3,468,530.14. The sale is made in connection with a selling plan dated February 24, 2026, intended to comply with Rule 10b5-1(c). The shares were acquired as compensation through performance awards on May 8, 2025, February 11, 2026, and May 6, 2026.
Key Figures
Key Terms
Rule 10b5-1(c) regulatory
Performance Awards financial
Aggregate Market Value financial
Gross Proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.